Obstructive Sleep Apnea (OSA) Treated With a Potassium Channel Inhibitor

NCT03603678 | Completed Phase 2 DMC

• 2 other identifiers: 190382017-001851-29
• Study Type: interventional
• Target: 34
• Locations: 2 countries
• Sites: 2

Brief Summary

The aim of this study in subjects with obstructive sleep apnea is to investigate pharmacodynamics, safety and tolerability after a single nasal administration of BAY2253651 and to evaluate first safety and tolerability of multiple dosing over 5 consecutive nights in OSA patients.

Conditions

Sleep Apnea, Obstructive

Keywords

Obstructive sleep apnea; Potassium channel blocker; Polysomnography; PSG

Outcome Measures

Primary Outcomes (1)

• Rate of responders, defined by reduction of apnoea-hypopnoea-index (AHI) from baseline by ≥ 50%

  2 days

Secondary Outcomes (2)

• Incidence of treatment emergent adverse events (TEAEs)

  Up to 7 days

• Severity of treatment emergent adverse events (TEAEs)

  Up to 7 days

Study Arms (3)

Part A single dose BAY2253651

EXPERIMENTAL

Single dose BAY2253651

Drug: BAY2253651

Part A single dose Placebo

PLACEBO COMPARATOR

Single dose matching placebo

Drug: Placebo

Part B multiple dose BAY2253651

EXPERIMENTAL

Multiple dose BAY2253651 on 5 consecutive nights

Drug: BAY2253651

Interventions

BAY2253651 DRUG

100 µg (500 µg/ml \* 200 µl) BAY2253651 intranasally

Part A single dose BAY2253651; Part B multiple dose BAY2253651

Placebo DRUG

Matching Placebo dosing

Part A single dose Placebo

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects need to be diagnosed with OSA (obstructive sleep apnea) but should be otherwise healthy at the discretion of the investigator.
• Patients must be pretreated with CPAP (continuous positive airway pressure) for OSA for at least 3 months before randomization.
• AHI of 15-50 per hour after 48 hours of CPAP withdrawal documented by baseline PSG (polysomnography, evaluated by the site staff) and at least 4 hours of total sleep time. (One retesting allowed).
• Female subjects must be of non-childbearing potential, i.e. post-menopausal (no menses for at least 1 year prior to randomization) or surgically sterile (tubal ligation, hysterectomy or bilateral oophorectomy)
• Men of reproductive potential together with their female partner(s) must agree to use at least two adequate contraception methods when sexually active. This applies for the time period between signing of the informed consent form and 3 months after the last administration of study drug.
• Acceptable methods of contraception include, but are not limited to, (i) condoms (male or female) with or without a spermicidal agent; (ii) diaphragm or cervical cap with spermicide; (iii) intra-uterine device; (iv) hormone-based contraception
• Only Part B: Patients having completed Part A and had valid PSG after dosing in Part A.

You may not qualify if:

• Inability to comply with planned study procedures or to comply with study protocol requirements; this includes completing required data collection and attending required follow up study visits.
• Neck circumference above/equal 44 cm.
• Not predominantly obstructive sleep apnea evidenced by baseline PSG.
• Severely impaired breathing within two days prior to randomization (e.g. acute nasal congestion during upper airway infection).
• Subject with known allergies or hypersensitivities to the study drugs (active substances or excipients of the preparations). Known severe respiratory tract allergies e.g. allergic asthma.
• Intake of a nasal decongestant during the intervention time (48 hours before visit 1 until end of visit 2).
• Use of any topical medication containing local anesthetics for nose and throat within 7 days before first investigational medicinal product (IMP) administration.
• Participation in another trial with an investigational drug within 30 days or 5 half-lives of the investigational drug, whichever is longer before first application of study drug or concomitant participation in another clinical study with investigational medicinal product(s).
• Any other condition, which would make the subject unsuitable for this study and will not allow participation for the full planned study period (e.g. active malignancy or other condition limiting life expectancy to less than 12 months)
• Known history of severe heart failure (NYHA 3-4) or severe COPD (GOLD 3-4).
• Heavy smoking, i.e. more than 20 cigarettes per day and/or unable to stop smoking during the stay in the sleep laboratory.
• Suspicion of drug or alcohol abuse.
• Regular daily consumption of more than 1 L of xanthine-containing beverages.

Sponsors & Collaborators

• Bayer: lead

Study Sites (2)

University Hospital Zürich

Zurich, 8091, Switzerland

Location

Oxford University Hospitals

Oxford, OX9 3DU, United Kingdom

Location

Related Publications (1)

• Gaisl T, Turnbull CD, Weimann G, Unger S, Finger R, Xing C, Cistulli PA, West S, Chiang AKI, Eckert DJ, Stradling JR, Kohler M. BAY 2253651 for the treatment of obstructive sleep apnoea: a multicentre, double-blind, randomised controlled trial (SANDMAN). Eur Respir J. 2021 Nov 18;58(5):2101937. doi: 10.1183/13993003.01937-2021. Print 2021 Nov.

  PMID: 34531274 DERIVED

MeSH Terms

Conditions

Sleep Apnea, Obstructive

Condition Hierarchy (Ancestors)

Sleep Apnea Syndromes; Apnea; Respiration Disorders; Respiratory Tract Diseases; Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders; Nervous System Diseases

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 21, 2018
• First Posted: July 27, 2018
• Study Start: August 13, 2018
• Primary Completion: May 23, 2019
• Study Completion: September 2, 2019
• Last Updated: December 11, 2020

Record last verified: 2020-12

Locations

CH (1); GB (1)